Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation (BSX) Free cash flow margin
Boston Scientific Corporation's free cash flow margin over the twelve months to 30 June 2026 was 17.3%, down 1.0 percentage points from fiscal 2025 (18.2%). Over the past ten years it has ranged from 0.08% (fiscal 2018) to 18.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −7.24% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 18.2% | 2.43 |
| FY2024 | 15.8% | 3.21 |
| FY2023 | 12.6% | 5.09 |
| FY2022 | 7.49% | (3.70) |
| FY2021 | 11.2% | (0.35) |
| FY2020 | 11.5% | (1.33) |
| FY2019 | 12.9% | 12.79 |
| FY2018 | 0.08% | (12.15) |
| FY2017 | 12.2% | 2.27 |
| FY2016 | 9.96% | 4.02 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| DXCM DexCom, Inc. compare | 28.3% |
| EW Edwards Lifesciences Corporation compare | 22.0% |
| SYK Stryker Corporation compare | 18.2% |
| BSX Boston Scientific Corporation | 17.3% |
| ABT Abbott Laboratories compare | 16.8% |
| MDT Medtronic PLC compare | 16.3% |
| STE STERIS plc compare | 15.5% |
| PHG Koninklijke Philips N.V. compare | 8.99% |
| GEHC GE HealthCare Technologies Inc. compare | 7.42% |
| Medical Devices industry median | −7.24% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on BSX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement